Literature DB >> 34918284

Clinical Staging of Ovarian Cancer.

Andrea S O'Shea1.   

Abstract

Ovarian cancer may arise from any of the histologic portions of the ovary including the epithelium, stroma, or germ cells. Of these, high-grade serous carcinoma arising from the epithelium of the ovary is the most common type. The clinical management and prognosis of ovarian cancer depend upon the stage of the cancer. Cancer stage is the extent to which the cancer has spread from its site of origin. For ovarian cancer, staging guidelines are determined by FIGO, the Fédération Internationale de Gynécologie et d'Obstétrique. The stage of ovarian cancer is determined by performing surgery to remove the ovaries and other gynecologic organs as well as lymph nodes and other tissues where the cancer may have spread. The histologic specimens from this surgery provide information from which the stage can be determined. In more advanced cases, this surgery may also include procedures to remove other areas of cancer. The stage of ovarian cancer guides treatment and is also the most important factor in ovarian cancer prognosis. Most epithelial ovarian cancers are diagnosed in advanced stages and are treated with surgery and chemotherapy. Despite aggressive treatment, the survival of patients with advanced stage epithelial ovarian cancer remains low, and more effective diagnostic and therapeutic approaches are needed.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Epithelial ovarian cancer; International Federation of Gynecology and Obstetrics (FIGO); Ovarian cancer; Staging; Surgical staging

Mesh:

Year:  2022        PMID: 34918284     DOI: 10.1007/978-1-0716-1956-8_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

2.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Authors:  Philipp Harter; Jalid Sehouli; Domenica Lorusso; Alexander Reuss; Ignace Vergote; Christian Marth; Jae-Weon Kim; Francesco Raspagliesi; Björn Lampe; Giovanni Aletti; Werner Meier; David Cibula; Alexander Mustea; Sven Mahner; Ingo B Runnebaum; Barbara Schmalfeldt; Alexander Burges; Rainer Kimmig; Giovanni Scambia; Stefano Greggi; Felix Hilpert; Annette Hasenburg; Peter Hillemanns; Giorgio Giorda; Ingo von Leffern; Carmen Schade-Brittinger; Uwe Wagner; Andreas du Bois
Journal:  N Engl J Med       Date:  2019-02-28       Impact factor: 91.245

6.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

7.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.

Authors:  R C Young; L A Walton; S S Ellenberg; H D Homesley; G D Wilbanks; D G Decker; A Miller; R Park; F Major
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

8.  Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.

Authors:  Kathleen M Schmeler; Xia Tao; Michael Frumovitz; Michael T Deavers; Charlotte C Sun; Anil K Sood; Jubilee Brown; David M Gershenson; Pedro T Ramirez
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

9.  Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.

Authors:  Philippe Morice; Franklin Joulie; Sophie Camatte; David Atallah; Roman Rouzier; Patricia Pautier; Christophe Pomel; Catherine Lhommé; Pierre Duvillard; Damienne Castaigne
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

10.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

View more
  2 in total

1.  Prediction Performance of Deep Learning for Colon Cancer Survival Prediction on SEER Data.

Authors:  Surbhi Gupta; S Kalaivani; Archana Rajasundaram; Gaurav Kumar Ameta; Ahmed Kareem Oleiwi; Betty Nokobi Dugbakie
Journal:  Biomed Res Int       Date:  2022-06-16       Impact factor: 3.246

Review 2.  Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook.

Authors:  Yongsheng Ruan; Libai Chen; Danfeng Xie; Tingting Luo; Yiqi Xu; Tao Ye; Xiaona Chen; Xiaoqin Feng; Xuedong Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-07       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.